ACE2 and endothelial dysfunction: We have also previously shown that global coagulation assays have the potential to be biomarkers of cardiovascular disease [19,20], and considering the importance of Virchow’s triad, a triad of flow stasis, hypercoagulability and endothelial dysfunction, in the development of thrombosis, further studies looking at the combination of global coagulation assays and endothelial biomarkers such as ACE2 to predict future cardiovascular outcomes are underway [33].